Toric Implantable Phakic Contact Lens in the Correction of Stable Keratoconus after Corneal Collagen Crosslinking

The study aims to evaluate the safety profile and efficacy of toric Implantable Phakic Contact Lens (IPCL) in patients with stable keratoconus after corneal collagen crosslinking (CXL).

A prospective interventional case series study involving 30 keratoconic eyes between 22 to 39 years of age implanted with toric IPCL 6 months after CXL. The refractive error, visual acuity, corneal endothelium, intraocular pressure (IOP), and adverse effects were observed for 12 months following the implantation.

The preoperative mean for the sphere was approximately -8.3±3.6, which improved postoperatively by -0.58±0.23 after 1 month, -0.48±0.19 after 3 months, -0.36±0.18 after 6 months, and -0.35±0.2 after 12 months respectively. About the cylinder, the preoperative mean for the cylinder was approximately -3.4±1.6, which improved postoperatively by -1.06±0.3 after 1 month, -0.76±0.19 after 3 months, -0.48±0.28 after 6 months and -0.53±0.12 after 12 months, respectively. The preoperative BCDVA was 0.34±0.13, which increased postoperatively to 0.18±0.11 after 12 months. The mean values for IOP were 14.5±1.5 mm Hg, 15.1±2.09 mm Hg, 13.8±2.2 mmHg, 13.3±1.7 mm Hg, 13.1±1.6 mm Hg at preoperative period, 1 month, 3 months, 6 months and 12 months postoperatively. The mean preoperative endothelial count was 2912.9±111.1 per square millimeter, 2854.7±113.2 cells per square millimeter after 6 months, and 2829.0±112.2 cells per square millimeter after 12 months.

Toric IPCL is a safe approach for treating residual refractive errors, particularly astigmatism, after 6 months of CXL in patients with stable KCS.